Department of Pathology, University of Washington School of Medicine, Seattle, Washington 98104, USA.
Mov Disord. 2010 Nov 15;25(15):2682-5. doi: 10.1002/mds.23287.
We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF Aβ(42), total tau (T-tau), and phospho-tau (P181-tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls ≤50 years (35), Controls >50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Aβ(42) was reduced in PD-CIND (P < 0.05) and PD-D (P < 0.01), whereas average CSF T-tau and P181-tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Aβ(42) may be a common feature of PD-CIND and PD-D.
我们验证了这样一个假设，即与阿尔茨海默病（AD）相关的脑脊液生物标志物特征存在于帕金森病和痴呆（PD-D）或帕金森病和认知障碍但无痴呆（PD-CIND）的一部分个体中。我们使用市售试剂盒定量测定脑脊液 Aβ（42）、总 tau（T-tau）和磷酸化 tau（P181-tau）。样本来自七个组的 345 个人（n）：≤50 岁的对照组（35 人）、>50 岁的对照组（115 人）、遗忘型轻度认知障碍（aMCI）（24 人）、AD（49 人）、PD（49 人）、PD-CIND（62 人）和 PD-D（11 人）。与年龄匹配或更年轻的对照组相比，我们观察到 AD 或 aMCI 的预期变化。PD-CIND（P < 0.05）和 PD-D（P < 0.01）患者的脑脊液 Aβ（42）减少，而平均脑脊液 T-tau 和 P181-tau 不变或减少。三分之一的 PD-CIND 和一半的 PD-D 患者具有 AD 的生物标志物特征。Aβ（42）代谢异常可能是 PD-CIND 和 PD-D 的共同特征。
